Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3GO0J)

Drug Name
Sodium taurocholate Drug Info
Synonyms Sodium taurocholate (rectal gel, diabetes/ obesity)
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 1/2 [1]
Cross-matching ID
PubChem CID
23666345
ChEBI ID
CHEBI:36276
CAS Number
CAS 145-42-6
TTD Drug ID
DM3GO0J
VARIDT Drug ID
DR00053

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Solid tumour/cancer 2A00-2F9Z Approved [12]
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [13]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [14]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [15]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [16]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [17]
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [18]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [19]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [20]
Oxaliplatin DMQNWRD Colorectal cancer 2B91.Z Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [22]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [23]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [24]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [25]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [24]
Pravastatin DM6A0X7 Hypercholesterolaemia 5C80.0 Approved [26]
Mycophenolate mofetil DMPQAGE Organ transplant rejection NE84 Approved [27]
Atorvastatin DMF28YC Cardiovascular disease BA00-BE2Z Approved [28]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [29]
Pitavastatin calcium DM1UJO0 Dyslipidemia 5C80-5C81 Approved [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug resistance-associated protein 3 (ABCC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [30]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [31]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [32]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [33]
Ezetimibe DM7A8TW Hypercholesterolaemia 5C80.0 Approved [34]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [35]
Morphine DMRMS0L Chronic pain MG30 Approved [36]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [37]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [38]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pravastatin DM6A0X7 Hypercholesterolaemia 5C80.0 Approved [5]
Ezetimibe DM7A8TW Hypercholesterolaemia 5C80.0 Approved [40]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [40]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [40]
Taurocholic acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [41]
Drug(s) Transported By Sodium/taurocholate cotransporting polypeptide (SLC10A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [42]
Pitavastatin calcium DM1UJO0 Dyslipidemia 5C80-5C81 Approved [43]
Rosuvastatin DMMIQ7G Hypercholesterolaemia 5C80.0 Approved [44]
Liothyronine DM6IR3P Hypothyroidism 5A00 Approved [45]
Estrone sulfate DMVBIZL Menopausal and postmenopausal disorder GA30 Approved [46]
Taurocholic acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [47]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Transported By Apical sodium-dependent bile acid transporter (SLC10A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic acid DM7OKQV Peroxisomal disorder 5C57 Approved [48]
Deoxycholic acid DM3GYAL N. A. N. A. Approved [49]
Taurocholic acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [3]
Glycodeoxycholic acid DM1XEJV Discovery agent N.A. Investigative [48]
Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [50]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [51]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [52]
Atorvastatin DMF28YC Cardiovascular disease BA00-BE2Z Approved [53]
Pitavastatin calcium DM1UJO0 Dyslipidemia 5C80-5C81 Approved [43]
Rosuvastatin DMMIQ7G Hypercholesterolaemia 5C80.0 Approved [44]
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [54]
Enalapril DMNFUZR Hypertension BA00-BA04 Approved [55]
Cholic acid DM7OKQV Peroxisomal disorder 5C57 Approved [9]
Liothyronine DM6IR3P Hypothyroidism 5A00 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [11]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [24]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [57]
Diclofenac DMPIHLS Osteoarthritis FA00-FA05 Approved [58]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [24]
Pravastatin DM6A0X7 Hypercholesterolaemia 5C80.0 Approved [59]
Mycophenolate mofetil DMPQAGE Organ transplant rejection NE84 Approved [27]
Atorvastatin DMF28YC Cardiovascular disease BA00-BE2Z Approved [29]
Erythromycin DM4K7GQ Bacterial infection 1A00-1C4Z Approved [60]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporting polypeptide 2B1 (SLCO2B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [61]
L-glutamic acid DM4PUDW Schizophrenia 6A20 Approved [62]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [63]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [25]
Pravastatin DM6A0X7 Hypercholesterolaemia 5C80.0 Approved [8]
Atorvastatin DMF28YC Cardiovascular disease BA00-BE2Z Approved [64]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [65]
Pitavastatin calcium DM1UJO0 Dyslipidemia 5C80-5C81 Approved [66]
Digoxin DMQCTIH Arrhythmia BC9Z Approved [67]
Rosuvastatin DMMIQ7G Hypercholesterolaemia 5C80.0 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By ATP-binding cassette sub-family A member 8 (ABCA8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estrone sulfate DMVBIZL Menopausal and postmenopausal disorder GA30 Approved [2]
Aminohippuric acid DMUN54G Discovery agent N.A. Investigative [2]
3R14S-OCHRATOXIN A DM2KEW6 Discovery agent N.A. Investigative [2]
Drug(s) Transported By Organic solute transporter subunit beta (SLC51B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [69]
Digoxin DMQCTIH Arrhythmia BC9Z Approved [69]
Estrone sulfate DMVBIZL Menopausal and postmenopausal disorder GA30 Approved [69]
Taurocholic acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [69]
Drug(s) Targeting G-protein coupled bile acid receptor 1 (GPBAR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29649907-Compound-INT767 DMA0RI8 N. A. N. A. Patented [70]
PMID29649907-Compound-8 DMV2D5M N. A. N. A. Patented [70]
INT-767 DMRJ9P4 Hepatic fibrosis DB93.0 Preclinical [71]
XL475 DMD8TNK Type-2 diabetes 5A11 Preclinical [72]
INT-777 DMTPB8A Metabolic disorder 5C50-5D2Z Investigative [73]
Bile acid DMIY2HW Discovery agent N.A. Investigative [74]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G-protein coupled bile acid receptor 1 (GPBAR1) TTSDVTR GPBAR_HUMAN Modulator [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
ATP-binding cassette sub-family A member 8 (ABCA8) DT9NXMV ABCA8_HUMAN Substrate [2]
Apical sodium-dependent bile acid transporter (SLC10A2) DT7JELC NTCP2_HUMAN Substrate [3]
Organic solute transporter subunit beta (SLC51B) DT1V9AJ OSTB_HUMAN Substrate [4]
Bile salt export pump (ABCB11) DTJ0EW4 ABCBB_HUMAN Substrate [5]
Sodium/taurocholate cotransporting polypeptide (SLC10A1) DT56EKP NTCP_HUMAN Substrate [6]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [7]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [2]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [8]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]

References

1 Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
2 Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
3 Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
4 OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005 Dec;42(6):1270-9.
5 Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
6 Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
7 Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
8 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
9 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
10 Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
11 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
12 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
13 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
14 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
15 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
16 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
17 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
18 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
19 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
20 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
21 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
22 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
23 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
24 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
25 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
26 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
27 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
28 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
29 FDA Drug Development and Drug Interactions
30 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
31 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
32 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
33 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
34 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
35 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
36 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
37 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
38 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
39 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
40 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
41 Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.
42 Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
43 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
44 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
45 Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501.
46 Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22.
47 Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
48 Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
49 Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23.
50 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
51 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
52 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
53 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
54 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
55 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
56 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
57 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
58 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
59 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
60 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
61 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
62 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
63 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
64 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
65 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
66 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
67 Drug Interactions in Infectious Diseases.
68 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
69 Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
70 Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
71 FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137.
72 Clinical pipeline report, company report or official report of Exelixis (2011).
73 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 37).
74 Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21.